Allogene Therapeutics (ALLO) SVP granted options, RSUs and sells shares

Rhea-AI Filing Summary

Allogene Therapeutics SVP and Chief Technical Officer Benjamin Machinas Beneski reported new equity awards and a small share sale. On February 2, 2026, he sold 7,549 shares of common stock at a weighted average price of $1.73 solely to cover tax withholding on vesting restricted stock units, under a mandatory “sell to cover” arrangement rather than a discretionary trade. He received a stock option for 373,757 shares at $1.87 per share, vesting 25% on February 2, 2027 and the balance in 36 monthly installments. He was also granted 105,720 restricted stock units, each representing one share, vesting in four equal annual installments starting February 2, 2026, subject to continued service. Following these transactions, he directly owned 210,172 shares of common stock.

Insider Trade Summary

Net Seller: 7,549 shares ($13,060)

Net Sell 3 txns

Insider Beneski Benjamin Machinas

Role SVP, Chief Technical Officer

Sold 7,549 shs ($13K)

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to buy)	373,757	$0.00	--
Grant/Award	Restricted Stock Unit	105,720	$0.00	--
Sale	Common Stock	7,549	$1.73	$13K

Holdings After Transaction: Stock Option (Right to buy) — 373,757 shares (Direct); Restricted Stock Unit — 105,720 shares (Direct); Common Stock — 210,172 shares (Direct)

Footnotes (1)

1. Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.71 to $1.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. 25% of the shares subject to the stock option shall vest on February 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter. Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal annual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Beneski Benjamin Machinas

(Last) (First) (Middle)

210 EAST GRAND AVENUE

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Allogene Therapeutics, Inc. [ ALLO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Technical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		S		7,549(1)	D	$1.73(2)	210,172	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to buy)	$1.87	02/02/2026		A		373,757		(3)	02/02/2036	Common Stock	373,757	$0	373,757	D
Restricted Stock Unit	(4)	02/02/2026		A		105,720		(4)	(4)	Common Stock	105,720	$0	105,720	D

Explanation of Responses:

1. Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.71 to $1.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

3. 25% of the shares subject to the stock option shall vest on February 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter.

4. Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal annual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date.

Remarks:

	/s/Earl Douglas, Attorney-in-Fact	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Allogene Therapeutics (ALLO) report for Benjamin Machinas Beneski?

Beneski reported one sale and two equity grants. He sold 7,549 common shares, received a 373,757-share stock option at $1.87, and 105,720 restricted stock units, all reported as directly owned positions after the transactions on February 2, 2026.

Why did Allogene Therapeutics SVP Benjamin Machinas Beneski sell 7,549 ALLO shares?

The share sale covered tax withholding obligations. The 7,549 shares were sold under a mandatory “sell to cover” election tied to vesting restricted stock units, meaning it was not a discretionary trade but required by the company’s equity incentive plan.

What stock option grant did Allogene’s SVP receive according to this Form 4?

Beneski received a stock option for 373,757 shares at $1.87. Twenty-five percent of the option vests on February 2, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter, providing a long-term incentive tied to continued service.

How do the new Allogene Therapeutics RSUs for Benjamin Machinas Beneski vest?

He was granted 105,720 restricted stock units. Each RSU represents one share of common stock and will vest in four equal annual installments over four years starting February 2, 2026, contingent on his continued service through each vesting date.

How many Allogene Therapeutics common shares does Beneski own after these transactions?

After the reported transactions, Beneski directly owned 210,172 common shares. This balance reflects his holdings following the 7,549-share tax-related sale and the vesting-related activity disclosed for February 2, 2026 in the Form 4 filing.

Are the Allogene Therapeutics insider transactions direct or indirect holdings?

All reported positions are held directly by Beneski. The Form 4 lists the common stock, stock option, and restricted stock units with ownership form marked as “D” for direct, with no indication of trusts or other indirect holding entities in the disclosure.